Medical Design Technology

News

Subscribe to MDT Magazine News

Down with jet lag

June 25, 2010 7:35 am | by EurekAlert | Comments

(Max-Planck-Gesellschaft) The active agent metyrapone influences corticosterone synthesis and enables faster adaptation to altered circadian rhythms.

TOPICS:

HeartWare names Larkin as board chairman

June 25, 2010 7:35 am | by Mass High Tech: The Journal of New England Technology | Comments

HeartWare International Inc., a Framingham maker of heart devices, has appointed board member C. Raymond Larkin, Jr. to the role of chairman of the board.

TOPICS:

Federal Register: Termination of Declarations Justifying Emergency Use Authorizations of Certain In Vitro Diagnostic Devices, Antiviral Drugs, and Personal Respiratory Protect...

June 25, 2010 7:34 am | by U.S. Food & Drug Administration | Comments

The FDA is issuing this notice, under the Federal Food, Drug, and Cosmetic Act (the act), of the termination of the declarations of emergency justifying Emergency Use Authorizations (EUAs) of certain in vitro diagnostic devices, personal respiratory...

Advertisement

Federal Register: Guidance for Industry and Food and Drug Administration Staff; In Vitro Diagnostic Studies--Frequently Asked Questions; Availability

June 25, 2010 7:34 am | by U.S. Food & Drug Administration | Comments

FDA is issuing this guidance to assist manufacturers in developing and conducting studies for IVD devices, particularly those exempt from most of the Investigational Device Exemption (IDE) regulations. The guidance explains data considerations that...

Global Manufacturing Competitiveness Index

June 25, 2010 7:34 am | by Material Handling Industry of America | Comments

A report from Deloitte's Global Manufacturing Industry group and the U.S. Council on Competitiveness indicates that access to talented workers capable of supporting innovation is the key factor driving global competitiveness at manufacturing companies-well

Epidemic played large role in shift of attitudes on abortion, author says

June 25, 2010 6:35 am | by EurekAlert | Comments

(University of Illinois at Urbana-Champaign) Ten years before the 1973 Supreme Court decision legalizing abortion, German measles probably played the biggest part in starting to shift public attitudes about the criminal abortion laws, University of Illinois historian Leslie J....

TOPICS:

A life-changing partnership

June 25, 2010 6:35 am | by EurekAlert | Comments

(European Molecular Biology Laboratory) Researchers at EMBL Heidelberg identified a novel regulatory protein complex in Drosophila that explains another protein's double life, and which likely plays an important role in mammals, too.

TOPICS:

Eyegate Pharma begins trial for dry eye drug

June 25, 2010 6:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Eyegate Pharmaceuticals Inc. has launched a Phase 3 clinical trial for its drug target, called EGP-437, to treat dry eye syndrome. The drug candidate is a type of steroid, delivered using the company's proprietary, non-invasive delivery system, known as Eyegate II.

Advertisement

United Seating & Mobility Launches New Company Website and E-Commerce Store at www.UnitedSeating.com

June 25, 2010 6:34 am | by Bio-Medicine.Org | Comments

ALBUQUERQUE, N.M. , June 25 /- United Seating & Mobility, the nation's largest privately-owned mobility and rehab equipment supplier, launched a newly redesigned website today at www.UnitedSeating.com . The new site features in-depth information for clients, families, and clinicians,...

TOPICS:

Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting

June 25, 2010 6:34 am | by Bio-Medicine.Org | Comments

CAMBRIDGE, Mass. , June 25 /- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for...

TOPICS:

Leading Experts to Speak at Focused Ultrasound Symposium

June 25, 2010 6:33 am | by Bio-Medicine.Org | Comments

Focused Ultrasound Surgery Foundation Announces Speakers, Moderators and Panelists for 2nd International Symposium on MR-Guided Focused Ultrasound CHARLOTTESVILLE, Va. , June 25 /PRNewswire-USNewswire/ -- Leading research and clinical experts from around the world are scheduled to speak...

TOPICS:

CGI Pharma to be sold to Calif. firm for $120M

June 25, 2010 5:35 am | by Mass High Tech: The Journal of New England Technology | Comments

CGI Pharmaceuticals Inc., a small-molecule-focused biotech in Branford, Conn., has signed a deal to be acquired by Gilead Sciences Inc. for up to $120 million. The buyout is planned to close in the third quarter of 2010.

Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain

June 25, 2010 5:34 am | by Bio-Medicine.Org | Comments

READING, England , June 25, 2010 /- Archimedes Pharma ("Archimedes"), a leading specialty pharma company, today announced that its lead product, PecFent*, has received a Positive Opinion from the Committee for Human Medicinal Products (CHMP), of the European Medicines Agency (EMA). The...

TOPICS:

Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVaxâ„¢ Administration

June 25, 2010 5:34 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J. , June 25 /- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today the publication of an article in the June 2010 edition of Vaccine , which describes protection from mucosal and systemic ricin...

TOPICS:

Phase 1 trial triggers $1M payment for ImmunoGen

June 25, 2010 5:34 am | by Mass High Tech: The Journal of New England Technology | Comments

Biotech firm ImmunoGen Inc. is in line for a $1 million milestone payment from sanofi-aventis, now that sanofi has launched a Phase 1 clinical trial of ImmunoGen's SAR650984 investigational antibody.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading